Themis announced the close of a Series C financing round led by Global Health Investment Fund (GHIF) as a new investor in the company. Glenn Rockman, Partner at GHIF, will join Themis’ Supervisory Board. The Series C proceeds will be used to advance Themis’ clinical and pre-clinical vaccine development programs.